SEC Form 4 · accession 0001209191-18-034051
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shane Ward
Officer — Sr. VP and General Counsel
Period of report
May 29, 2018
Accepted (ET)
May 29, 2018 · 9:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 29, 2018 | A | 10,000 | $0.00 | A | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $7.95 | May 29, 2018 | A | 120,000 | A | — | May 28, 2028 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments on each anniversary of May 29, 2018.
- F225% of the shares subject to the stock option vest and become exercisable on May 29, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.